Business Context and Reporting Period
This Form 8-K is filed by Seer, Inc. on March 30, 2026, reporting an event that occurred on March 23, 2026. The filing addresses a legal proceeding regarding the company's intellectual property portfolio, specifically U.S. Patent No. 11,435,360 B2, which relates to particle proteomics technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event and does not contain financial statement data.
Material Changes and Legal Proceedings
The primary material event is the Final Written Decision issued by the Patent Trial and Appeal Board (PTAB) in an inter partes review (IPR2024-01473) initiated by PreOmics GmbH and Biognosys AG.
- Outcome: The PTAB determined that petitioners failed to demonstrate the unpatentability of claims 2, 3, 7, 23, and 24.
- Patent Status: A total of 23 claims remain valid and enforceable (5 upheld claims plus 18 unchallenged claims).
- Invalidated Claims: Claims 1, 4, 6, 22, 24, and 25 were determined to be unpatentable.
- Technical Scope: Upheld claims include limitations regarding the depth and dynamic range of proteins detected and the nature of particles used.
Outlook, Risks, and Contingencies
Appeal Deadline: Either party may pursue an appeal by filing a notice of appeal by May 25, 2026.
Risk Assessment: While the core patent claims were largely upheld, the invalidation of specific claims (1, 4, 6, 22, 24, 25) and the potential for an appeal introduce uncertainty regarding the full scope of the company's intellectual property protection.
Investor Verification Checklist
- Verify the specific technical limitations of the upheld claims (2, 3, 7, 23, 24) to assess their impact on Seer's competitive moat.
- Monitor for a notice of appeal from PreOmics GmbH or Biognosys AG before the May 25, 2026 deadline.
- Review the attached press release (Exhibit 99.1) for management's detailed commentary on the decision.
- Assess whether the invalidated claims were critical to current or future product commercialization.